How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Flu Shots Market
- By Vaccine Type: Trivalent Influenza Vaccine (TIV), Quadrivalent Influenza Vaccine (QIV), Live Attenuated Influenza Vaccine (LAIV), High-Dose Influenza Vaccine, Adjuvanted Influenza Vaccine
- By Age Group: Pediatric (6 months to 17 years), Adult (18 to 64 years), Geriatric (65 years and above)
- By End User: Hospitals, Clinics and Physician Offices, Pharmacies, Public Health Clinics, Occupational Health Centers
- By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Direct Sales to Healthcare Providers
- By Technology Platform: Inactivated Influenza Vaccine (IIV), Recombinant Influenza Vaccine (RIV), Live Attenuated Influenza Vaccine (LAIV)
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Trivalent Influenza Vaccine (TIV) leads By Vaccine Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 293 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.178 →
- 12 Company Profiles 15 players: SWOT & benchmarking p.186 →
Full report · locked preview
Everything inside the Flu Shots Market report
A complete, evidence-based study - 12 chapters and 123 sections covering market size, segmentation across 5 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Vaccine Type 5
Age Group 3
End User 5
Distribution Channel 4
Technology Platform 3
Companies profiled
Sanofi Pasteur
GlaxoSmithKline (GSK)
Seqirus (a CSL company)
AstraZeneca
Pfizer
Moderna
Bharat Biotech
Novavax
Baxter International
Mylan (now part of Viatris)
Johnson & Johnson
Sinovac Biotech
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Sanofi Pasteur
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →GlaxoSmithKline (GSK)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Seqirus (a CSL company)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →AstraZeneca
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Pfizer
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Moderna
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Bharat Biotech
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Novavax
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Baxter International
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Mylan (now part of Viatris)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Johnson & Johnson
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Sinovac Biotech
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Sinopharm Group
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Boehringer Ingelheim
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Takeda Pharmaceutical
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$7,306M by 2033 · 6.6% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Trivalent Influenza Vaccine (TIV)55.6
- Quadrivalent Influenza Vaccine (QIV)13.5
- Live Attenuated Influenza Vaccine (LAIV)8.5
- High-Dose Influenza Vaccine13.2
- Adjuvanted Influenza Vaccine9.2
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,448M → $2,301M · 6.0%
Europe$1,009M → $1,829M · 7.7%
Asia Pacific$921.5M → $1,529M · 6.5%
Latin America$570.4M → $871.6M · 5.4%
Middle East and Africa$438.8M → $651.5M · 5.1%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →6.542026
6.542027
6.562028
6.562029
6.582030
6.582031
6.602032
6.612033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Sanofi Pasteur12.9
- GlaxoSmithKline (GSK)21.6
- Seqirus (a CSL company)11.2
- AstraZeneca6.8
- Pfizer12.6
- Moderna7.0
- Others27.9
Segment contribution to growth (%)
Fig. 18 · p.39 →Vaccine Type26.1%
Age Group16.1%
End User27.7%
Distribution Channel11.9%
Technology Platform18.2%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America32.0
- Europe25.5
- Asia Pacific21.3
- Latin America12.1
- Middle East and Africa9.1
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Sanofi Pasteur | 77 | 98 | 90 | 85 | 95 | 94 | 90 |
| GlaxoSmithKline (GSK) | 86 | 85 | 88 | 76 | 68 | 73 | 79 |
| Seqirus (a CSL company) | 78 | 84 | 79 | 67 | 87 | 69 | 77 |
| AstraZeneca | 73 | 66 | 68 | 63 | 77 | 58 | 68 |
| Pfizer | 63 | 70 | 63 | 70 | 66 | 59 | 65 |
| Moderna | 65 | 53 | 55 | 69 | 47 | 68 | 60 |
| Bharat Biotech | 41 | 61 | 59 | 40 | 63 | 59 | 54 |
| Novavax | 50 | 52 | 47 | 45 | 44 | 48 | 48 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Sanofi Pasteur
- GlaxoSmithKline (GSK)
- Seqirus (a CSL company)
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Sanofi Pasteur | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| GlaxoSmithKline (GSK) | ◐ | ◐ | ◐ | ◐ | − | ✓ |
| Seqirus (a CSL company) | ◐ | ✓ | ✓ | ◐ | ✓ | − |
| AstraZeneca | ✓ | ◐ | ◐ | ◐ | ◐ | ◐ |
| Pfizer | ◐ | ✓ | − | ✓ | − | − |
| Moderna | ◐ | − | ◐ | ◐ | − | ✓ |
| Bharat Biotech | − | − | − | ◐ | ◐ | ◐ |
| Novavax | − | − | − | ◐ | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Sanofi Pasteur90
2GlaxoSmithKline (GSK)79
3Seqirus (a CSL company)77
4AstraZeneca68
5Pfizer65
6Moderna60
7Bharat Biotech54
8Novavax48
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Sanofi PasteurGlaxoSmithKline (GSK)
Challenger2
Strong scale, closing on the leaders.
Seqirus (a CSL company)AstraZeneca
Contender2
Focused players with pockets of strength.
PfizerModerna
Niche2
Specialists in a single segment or region.
Bharat BiotechNovavax
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Vaccine Type in North America, then scale across Flu Shots Market — a $397M beachhead inside a $5.44B market.
Beachhead (SOM)$397Mobtainable near-term
Serviceable (SAM)$2.17Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale5 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion87 fit
Trivalent Influenza Vaccine (TIV)
Best fit — highest urgency & budget in Vaccine Type.
Economic buyer78 fit
Quadrivalent Influenza Vaccine (QIV)
Strong fit — clear ROI and a fast path to value.
End user66 fit
Live Attenuated Influenza Vaccine (LAIV)
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Vaccine Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Age Group & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + End User
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales47%
Partner / channel28%
Digital / self-serve18%
Marketplaces7%
Positioning & messaging
§GTM 2 · p.194 →For Vaccine Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Flu Shots Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified45%
Sales qualified26%
Evaluation12%
Closed-won6%
$19.7KCAC
$69KLTV
3.5:1LTV : CAC
< 4 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Flu Shots Market is a durable-growth opportunity — $10.5B by 2033, compounding at 9.3%.
TAM · 2025$5.18Btoday
TAM · 2033$10.5Bforecast
CAGR9.3%2027–2033
Cumulative$68.2Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$10.5BTotal addressable market
SAM$3.94BServiceable available market
SOM$769MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →9.3% CAGR
Demand compounds through 2033, outpacing GDP across Vaccine Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Vaccine Type moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$10.5BLarge & growingTAM by 2033 at 9.3% CAGR
$3.94BServiceable nowreachable with today’s model
$769MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$8.21BBear6.0% CAGR
$10.5BBase9.3% CAGR
$13.5BBull12.2% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Age Group optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Flu Shots Market — a $971M market by 2033. Plan: grow share from 6.7% to 14.4%.
Market size · 2033$971Mtotal addressable
Market CAGR9.5%2027–2033
Target share14.4%from 6.7% today
Revenue ambition$140Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 6.7% | 14.4% | On track |
| Revenue | $69M | $140M | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Ahead |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | At risk |
| Gross margin | 29.1% | 43.0% | Behind |
| Customer retention | 87.7% | 96.5% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Vaccine Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Age Group capability
A defensible second engine — invest in Age Group to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Vaccine Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Age Group
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $17M capacity & capability investment
- Greenlight bolt-on M&A in Age Group
- Authorise North America expansion plan
- Fund R&D program for Vaccine Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAt risk
- Competitive share lossOn track
- Input-cost & supply riskAhead
- Regulatory / policy changeOn track
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Flu Shots Market conversation — a $4.71B market you can size, segment and defend in minutes.
Market size · 2033$4.71Btotal opportunity
Growth6.6%CAGR to 2033
Addressable buyers1,496+accounts in scope
Typical ROI6.8×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Vaccine Type
Goal Grow share in Vaccine Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →6.8×return on cost, year one
< 3 mopayback period
$41K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
Sanofi PasteurGlaxoSmithKline (GSK)Seqirus (a CSL company)AstraZenecaPfizerModernaBharat BiotechNovavax+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Flu Shots Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Flu Shots Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Flucloxacillin Market
Market size, share, segmentation and regional forecast.
$3.9B market · 2025 base year
View reportFelbinac (CAS 5728-52-9) Market
Market size, share, segmentation and regional forecast.
$5.8B market · 2025 base year
View reportGallbladder Cancer Therapeutics Market
Market size, share, segmentation and regional forecast.
$4.3B market · 2025 base year
View reportExenatide Drugs Market
Market size, share, segmentation and regional forecast.
$3.2B market · 2025 base year
View reportGallbladder Cancer Treatment Market
Market size, share, segmentation and regional forecast.
$4.3B market · 2025 base year
View reportGALNT1 Antibody Market
Market size, share, segmentation and regional forecast.
$1.9B market · 2025 base year
View reportGABA Receptor Agonist Drug Market
Market size, share, segmentation and regional forecast.
$2.0B market · 2025 base year
View reportAir Driven Handpiece Turbines Market
Market size, share, segmentation and regional forecast.
$6.1B market · 2025 base year
View reportFosfomycin Sodium Market
Market size, share, segmentation and regional forecast.
$2.1B market · 2025 base year
View reportAir Driven Handpiece Motors Market
Market size, share, segmentation and regional forecast.
$1.4B market · 2025 base year
View reportEnteric-coated Tablets Market
Market size, share, segmentation and regional forecast.
$2.0B market · 2025 base year
View reportEntereg (alvimopan) Market
Market size, share, segmentation and regional forecast.
$3.1B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.